Barclays
DTIL icon

Barclays’s Precision BioSciences DTIL Stock Holding History

Barclays’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89K Buy
11,322
+5,743
+103% +$40.4K ﹤0.01% 4094
2026
Q1 		$30.7K Buy
5,579
+368
+7% +$1.7K ﹤0.01% 4470
2025
Q4 		$21.7K Buy
5,211
+4,827
+1,257% +$27.4K ﹤0.01% 4862
2025
Q3 		$2.12K Hold
384
– – ﹤0.01% 5139
2025
Q2 		$1.61K Hold
384
– – ﹤0.01% 5048
2025
Q1 		$1.83K Sell
384
-2,486
-87% -$12.7K ﹤0.01% 5000
2024
Q4 		$10.9K Hold
2,870
– – ﹤0.01% 4984
2024
Q3 		$25.7K Hold
2,870
– – ﹤0.01% 4865
2024
Q2 		$27.9K Sell
2,870
-3
-0.1% -$35 ﹤0.01% 4378
2024
Q1 		$39K Sell
2,873
-4,278
-60% -$52.3K ﹤0.01% 4666
2023
Q4 		$78.3K Buy
7,151
+677
+10% +$7.3K ﹤0.01% 4692
2023
Q3 		$66.3K Hold
6,474
– – ﹤0.01% 3747
2023
Q2 		$102K Hold
6,474
– – ﹤0.01% 3552
2023
Q1 		$146K Buy
6,474
+4,901
+312% +$161K ﹤0.01% 3974
2022
Q4 		$56.2K Sell
1,573
-70
-4% -$2.77K ﹤0.01% 4509
2022
Q3 		$64K Sell
1,643
-6
-0.4% -$285 ﹤0.01% 3701
2022
Q2 		$79K Buy
1,649
+740
+81% +$43.4K ﹤0.01% 3861
2022
Q1 		$84K Sell
909
-1,608
-64% -$218K ﹤0.01% 3860
2021
Q4 		$559K Buy
2,517
+1,269
+102% +$354K ﹤0.01% 3156
2021
Q3 		$432K Buy
1,248
+1,022
+452% +$346K ﹤0.01% 3257
2021
Q2 		$86K Sell
226
-1,096
-83% -$329K ﹤0.01% 3906
2021
Q1 		$411K Buy
1,322
+512
+63% +$179K ﹤0.01% 3291
2020
Q4 		$202K Sell
810
-684
-46% -$168K ﹤0.01% 3757
2020
Q3 		$276K Buy
1,494
+655
+78% +$130K ﹤0.01% 3639
2020
Q2 		$210K Buy
839
+437
+109% +$95.7K ﹤0.01% 4032
2020
Q1 		$73K Sell
402
-802
-67% -$210K ﹤0.01% 4991
2019
Q4 		$501K Sell
1,204
-95
-7% -$29.8K ﹤0.01% 4300
2019
Q3 		$327K Sell
1,299
-42
-3% -$13.7K ﹤0.01% 4594
2019
Q2 		$533K Buy
+1,341
New +$540K ﹤0.01% 4264

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Barclays's DTIL Position: Q2 2026 in Review

Barclays increased its Precision BioSciences (DTIL) stake by 103% in Q2 2026, buying an estimated $40.4K and bringing the position to 11,322 shares worth $89K. The position accounts for ﹤0.01% of the portfolio, ranked #4094.

Barclays first reported a position in DTIL in Q2 2019 and has held it in 29 quarters since. The position peaked at $559K in Q4 2021. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Barclays held 11,322 shares of Precision BioSciences worth $89K as of Q2 2026.
  • Barclays bought 5,743 Precision BioSciences shares in Q2 2026, an estimated $40.4K.
  • Precision BioSciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4094 holding.
  • Barclays first reported a position in Precision BioSciences in Q2 2019 and has held it in 29 quarters since.
  • Barclays's Precision BioSciences position peaked at $559K in Q4 2021.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.